DDO-7263

DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD) [1][2].

Product Specifications

CAS Number

[2254004-96-9]

UNSPSC

12352005

Target

Keap1-Nrf2

Type

Reference compound

Related Pathways

NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ddo-7263.html

Purity

99.83

Solubility

DMSO : 17.86 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1=NC=C(C2=NOC(C3=CC(F)=C(C=C3)F)=N2)C=C1

Molecular Formula

C14H9F2N3O

Molecular Weight

273.24

References & Citations

[1]Zhen Dai, et al. Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome. J Med Chem. 2022 Mar 24;65 (6) :5029-5043.|[2]Li-Li Xu, et al. 5- (3,4-Difluorophenyl) -3- (6-methylpyridin-3-yl) -1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress. Free Radic Biol Med. 2019 Apr;134:288-303.